Jul 02

M.M DILLON & CO SERVES AS FINANCIAL ADVISOR TO INOVIO IN THE SPIN OFF OF GENEOS THERAPEUTICS, INC

MM Dillon advised Inovio in the spin-off of GENEOS Therapeutics, Inc., to develop and commercialize neo-antigen based personalized cancer therapies. While Inovio pursues the unique potential of its SynCon® immunotherapy design to break tolerance and create cancer products targeting universal tumor specific antigens, GENEOS will exclusively focus on leveraging Inovio’s potent DNA immunotherapy technology platform to advance the emerging field of patient-specific neo-antigen therapies. MM Dillon continues to advise Geneos on third party funding for its development.

About Inovio

Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of treating and preventing cancer and infectious diseases. Inovio’s technology platform is capable of activating antigen-specific immune responses. Aptly named ASPIRE™ (Antigen SPecific Immune REsponses), this unique technology is primed to change the way cancer and infectious disease are treated. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—ASPIRE is realizing the true promise of immunotherapy.

About M.M. Dillon & Co.

M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.

Leave a reply

Your email address will not be published. Required fields are marked *